{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Eng SE"],"funding":["United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs","U.S. Department of Health & Human Services | NIH | National Cancer Institute","NCI NIH HHS","Division of Cancer Prevention, National Cancer Institute","SPORE Career Enhancement Program"],"pagination":["65-72"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12356097"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(1)"],"pubmed_abstract":["Background
Protocol-based active surveillance (AS) biopsies have led to poor compliance. To move to risk-based protocols, more accurate imaging biomarkers are needed to predict upgrading on AS prostate biopsy. We compared restriction spectrum imaging (RSI-MRI) generated signal maps as a biomarker to other available non-invasive biomarkers to predict upgrading or reclassification on an AS biopsy.Methods
We prospectively enrolled men on prostate cancer AS undergoing repeat biopsy from January 2016 to June 2019 to obtain an MRI and biomarkers to predict upgrading. Subjects underwent a prostate multiparametric MRI and a short duration, diffusion-weighted enhanced MRI called RSI to generate a restricted signal map along with evaluation of 30 biomarkers (14 clinico-epidemiologic "],"journal":["Prostate cancer and prostatic diseases"],"pubmed_title":["Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy."],"pmcid":["PMC12356097"],"funding_grant_id":["P30CA016042","U01 CA214194","U01CA214194","P50 CA186786","P30 CA054174","U01CA214170","U01 CA214170","U24 CA115102","U24CA115102","U24 CA248265","P30 CA016042","U24 CA086368","U24CA086368","W81XWH-15-1-0441","P30CA054174"],"pubmed_authors":["Thompson IM","Chan DW","Troyer DA","Sokoll LJ","Lam A","Basasie B","Eng SE","Chinnaiyan AM","Sunnapwar AG","John Semmes O","Clarke GD","Tosoian JJ","Boutros PC","Liss MA","Johnson-Pais TL","Leach RJ","Siddiqui J"],"additional_accession":[]},"is_claimable":false,"name":"Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy.","description":"Background
Protocol-based active surveillance (AS) biopsies have led to poor compliance. To move to risk-based protocols, more accurate imaging biomarkers are needed to predict upgrading on AS prostate biopsy. We compared restriction spectrum imaging (RSI-MRI) generated signal maps as a biomarker to other available non-invasive biomarkers to predict upgrading or reclassification on an AS biopsy.Methods
We prospectively enrolled men on prostate cancer AS undergoing repeat biopsy from January 2016 to June 2019 to obtain an MRI and biomarkers to predict upgrading. Subjects underwent a prostate multiparametric MRI and a short duration, diffusion-weighted enhanced MRI called RSI to generate a restricted signal map along with evaluation of 30 biomarkers (14 clinico-epidemiologic ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-04-16T15:08:22.43Z","creation":"2026-04-07T14:12:17.59Z"},"accession":"S-EPMC12356097","cross_references":{"pubmed":["36097168"],"doi":["10.1038/s41391-022-00591-w"]}}